PL3582764T3 - Leczenie zaburzeń związanych ze spożywaniem alkoholu - Google Patents

Leczenie zaburzeń związanych ze spożywaniem alkoholu

Info

Publication number
PL3582764T3
PL3582764T3 PL18705913T PL18705913T PL3582764T3 PL 3582764 T3 PL3582764 T3 PL 3582764T3 PL 18705913 T PL18705913 T PL 18705913T PL 18705913 T PL18705913 T PL 18705913T PL 3582764 T3 PL3582764 T3 PL 3582764T3
Authority
PL
Poland
Prior art keywords
treatment
alcohol use
use disorder
disorder
alcohol
Prior art date
Application number
PL18705913T
Other languages
English (en)
Inventor
Bo SÖDERPALM
Andrea DE BEJCZY
Original Assignee
Bo SÖDERPALM
Andrea DE BEJCZY
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bo SÖDERPALM, Andrea DE BEJCZY filed Critical Bo SÖDERPALM
Publication of PL3582764T3 publication Critical patent/PL3582764T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL18705913T 2017-02-17 2018-02-16 Leczenie zaburzeń związanych ze spożywaniem alkoholu PL3582764T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1702590.9A GB2561333B (en) 2017-02-17 2017-02-17 Treatment of alcohol use disorder
PCT/EP2018/053914 WO2018149979A1 (en) 2017-02-17 2018-02-16 Treatment of alcohol use disorder
EP18705913.4A EP3582764B1 (en) 2017-02-17 2018-02-16 Treatment of alcohol use disorder

Publications (1)

Publication Number Publication Date
PL3582764T3 true PL3582764T3 (pl) 2021-10-04

Family

ID=58486991

Family Applications (1)

Application Number Title Priority Date Filing Date
PL18705913T PL3582764T3 (pl) 2017-02-17 2018-02-16 Leczenie zaburzeń związanych ze spożywaniem alkoholu

Country Status (11)

Country Link
US (1) US11318143B2 (pl)
EP (1) EP3582764B1 (pl)
JP (1) JP6877012B2 (pl)
CN (1) CN110325181B (pl)
DK (1) DK3582764T3 (pl)
ES (1) ES2880005T3 (pl)
GB (1) GB2561333B (pl)
HU (1) HUE054756T2 (pl)
PL (1) PL3582764T3 (pl)
PT (1) PT3582764T (pl)
WO (1) WO2018149979A1 (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220378777A1 (en) * 2019-10-31 2022-12-01 The Trustees Of Indiana University Compositions and methods for treating alcohol use disorder or a related condition thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101087464B1 (ko) 2003-08-08 2011-11-25 밸리언트 인터내셔널(바베이도스) 에스알엘 부프로피온 히드로클로라이드의 개질 방출형 정제
WO2006040680A1 (en) * 2004-10-15 2006-04-20 Pfizer Products Inc. Compositions and methods for intranasal, buccal, sublingual and pulmonary delivery of varenicline
US20080181933A1 (en) 2005-03-21 2008-07-31 Pfizer Inc. Chewing Gum Compositions of Varenicline
US20110086086A1 (en) 2005-07-26 2011-04-14 Pfizer Inc Transdermal system for varenicline
US20080044462A1 (en) 2006-04-06 2008-02-21 Collegium Pharmaceutical, Inc. Delaware Stabilized transdermal bupropion preparations
US8653271B2 (en) 2006-10-18 2014-02-18 University Of Kentucky Research Foundation Enhancing transdermal delivery of opioid antagonists and agonists using codrugs linked to bupropion or hydroxybupropion
WO2009034431A2 (en) 2007-09-10 2009-03-19 Pfizer Inc. Controlled-release dosage forms for varenicline

Also Published As

Publication number Publication date
WO2018149979A1 (en) 2018-08-23
CN110325181A (zh) 2019-10-11
HUE054756T2 (hu) 2021-09-28
GB201702590D0 (en) 2017-04-05
JP6877012B2 (ja) 2021-05-26
ES2880005T3 (es) 2021-11-23
DK3582764T3 (da) 2021-05-25
JP2020507609A (ja) 2020-03-12
GB2561333A (en) 2018-10-17
PT3582764T (pt) 2021-06-17
GB2561333B (en) 2020-06-03
CN110325181B (zh) 2022-10-04
US11318143B2 (en) 2022-05-03
US20200009153A1 (en) 2020-01-09
EP3582764B1 (en) 2021-03-31
EP3582764A1 (en) 2019-12-25

Similar Documents

Publication Publication Date Title
ZA202006746B (en) Methods of treatment
ZA201607415B (en) Antibody-drug-conjugate and its use for the treatment of cancer
PT3504187T (pt) Utilização da pridopidina no tratamento do declínio funcional
IL261959A (en) Cancer treatment with tg02
SG10202013034QA (en) Compositions, devices, and methods for the treatment of alcohol use disorder
SG11201609652RA (en) Treatment of polybacterials infections
PL3964213T3 (pl) Leczenie zaburzeń zachowania
SI3622953T1 (sl) Kombinirano zdravljenje raka
PT3661491T (pt) 3-metilmetcatinona para uso no tratamento de um indivíduo sob uma intervenção psicoterapêutica
IL263835A (en) Exosome-guided treatment of cancer
ZA201705847B (en) Treatment of pain
IL265259A (en) Treatment of multiple sclerosis with chs-131
SG11202005850VA (en) Methods of treatment of hypertrigl yceridemia
IL268187A (en) Use of Snickepok to treat stroke
IL266243A (en) Use of senicapoc for the treatment of neuropathic pain
EP3226886A4 (en) Use of fibulin-5 for the treatment of keloid scars
ZA201902085B (en) Medicinal use of serrulatane diterpenes
PT3582764T (pt) Tratamento da perturbação de uso de álcool
HK40006632A (en) Treatment of pain
SG10201913141UA (en) Treatment of alphavirus-induced inflammation
GB201621398D0 (en) Treatment of emt-associated disease
GB201622214D0 (en) treatment of cancer
AU2016901912A0 (en) Treatment of Pain
GB201604621D0 (en) Treatment of cancer
GB201604293D0 (en) Treatment of cancer